WallStSmart
MCRB

Seres Therapeutics Inc

NASDAQ: MCRB · HEALTHCARE · BIOTECHNOLOGY

$7.84
-3.21% today

Updated 2026-06-05

Market cap
$73.98M
P/E ratio
P/S ratio
64.50x
EPS (TTM)
$-5.20
Dividend yield
52W range
$7 – $30
Volume
0.1M

Seres Therapeutics Inc (MCRB) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20122013201420152016201720182019202020212022202320242025
Operating cash flow$-2.92M$-5.32M$-10.36M$-40.84M$43.92M$-75.52M$-62.85M$-76.52M$-93.61M$6.69M$-228.82M$-117.35M$-148.61M$1.12M
Capital expenditures$292000.00$174000.00$1.00M$4.36M$21.49M$4.68M$1.94M$1.00M$591000.00$9.57M$9.82M$7.97M$380000.00$252000.00
Depreciation$25000.00$88000.00$190000.00$728000.00$4.21M$7.26M$7.86M$7.60M$6.58M$5.95M$6.63M$6.24M$5.47M
Stock-based comp$28000.00$209000.00$2.07M$9.69M$16.86M$17.36M$16.64M$8.34M$8.82M$20.22M$25.48M$34.10M$20.97M$10.84M
Free cash flow$-3.22M$-5.50M$-11.36M$-45.21M$22.43M$-80.20M$-64.79M$-77.52M$-94.20M$-2.88M$-238.64M$-125.33M$-148.99M$865000.00
Investing cash flow$-319000.00$-184000.00$-1.10M$-137.13M$-65.45M$56.99M$112.32M$-30.52M$-158.89M$64.09M$82.43M$10.58M$142.29M
Financing cash flow$9.44M$944000.00$123.99M$137.72M$2.14M$83000.00$268000.00$86.23M$303.42M$1.18M$129.60M$71.70M$-90.37M
Dividends paid$262000.00$0.00$0.00
Share repurchases
Debt repayment
Net change in cash$-40.25M$-19.39M$-18.45M$49.73M$-20.81M$50.92M$71.95M$-16.79M

Frequently asked questions

What is Seres Therapeutics Inc's revenue?

Seres Therapeutics Inc's trailing twelve-month revenue is $1.15M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is MCRB?

In its most recent fiscal year, MCRB ran a gross margin of -423.83%, an operating margin of -11,910.14%, and a net margin of 721.93%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does MCRB generate?

MCRB produced $865000.00 in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MCRB's balance sheet healthy?

MCRB holds $45.77M in cash and equivalents against — in long-term debt, on $44.22M of shareholder equity. That debt is best read against the cash flow the business throws off each year.